This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
GS
Not CommonAI-summarized
Gloriosa superba
Gloriosa superba
Traditional African and Indian medicine for gout and pain in tiny doses
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Gloriosa superba is a perennial climbing plant containing the bioactive alkaloid colchicine, used both as a pharmaceutical source and in traditional medicine [PMID:28399663, PMID:35941253].
Background
Also known as the "gloriosa lily," "glory lily," or "tiger claw," Gloriosa superba is a perennial climber in the Liliaceae family found in tropical regions of Africa and South Asia [PMID:35941253, PMID:41306838].
Traditional uses
In African and Southeast Asian cultures, it is used as an ayurvedic medicinal herb to treat arthritis, gout, rheumatism, inflammation, ulcers, bleeding piles, skin diseases, leprosy, impotency, and snakebites [PMID:21059382, PMID:35941253].
Active compounds
The primary bioactive component is colchicine [PMID:35941253]. Other isolated compounds include gloriosine, colchicoside, superbine, lumicolchicine, 3-demethyl-N-deformyl-N-deacetylcolchicine, 3-demethylcolchicine, N-formyl deacetylcolchicine, and a new cytotoxic colchinoid named glorigerine [PMID:21059382, PMID:36533687].
Mechanism of action
Colchicine binds to tubulin dimers and inhibits microtubule assembly, acting as a mitotic poison and providing anti-inflammatory effects [PMID:34780686]. Gloriosine is suggested to have similar microtubule-targeting properties, binding to the colchicine binding site (CBS) of beta-tubulin [PMID:36964265].
Clinical evidence
Evidence CGout and Inflammatory Disorders
Colchicine, sourced from G. superba, is an FDA-approved treatment for inflammatory disorders including gouty arthritis and familial Mediterranean fever [PMID:34780686, PMID:28713407].
Evidence DCancer
Colchicine has antimitotic activity that prevents the growth of cancer cells [PMID:23210778]. Gloriosine showed significant antiproliferative activity against various human cancer cell lines with IC50 values from 32.61 to 100.28 nM [PMID:36033689]. Chitosan-encapsulated G. superba nanoparticles suppressed cervical cancer in HeLa cell lines by inhibiting the SKA3-mediated PI3K/AKT/mTOR pathway [PMID:40642599].
Evidence DPancreatic Adenocarcinoma
In a murine model, coadministration of G. superba extract improved the in vivo antitumoural activity of gemcitabine [PMID:27765363].
Safety & adverse effects
The plant is poisonous due to high colchicine concentrations [PMID:27324655]. Acute poisoning manifests within hours as vomiting, abdominal pain, and diarrhea, potentially progressing to bone marrow suppression, multi-organ failure, rhabdomyolysis, and disseminated intravascular coagulation [PMID:41306838, PMID:27049658]. A delayed effect of poisoning is dystrophic anagen effluvium (massive hair loss) occurring weeks after acute symptoms [PMID:41306838, PMID:26060369]. Case fatality for self-poisoning in one study was 10% [PMID:30888889].
Evidence summary
Evidence consists primarily of pharmacological reviews, in vitro studies, animal models, and clinical case reports of poisoning; there are no high-level human clinical trials provided for the whole herb.
PubMed sources
1.PMID: 28399663 (2018) — Upstream biomanufacturing of pharmaceutical colchicine. · Critical reviews in biotechnology
2.PMID: 41306838 (2025) — Gloriosa superba Poisoning-induced Anagen Effluvium. · International journal of trichology
3.PMID: 35941253 (2022) — In vitro propagation and secondary metabolite production in Gloriosa superba L. · Applied microbiology and biotechnology
4.PMID: 28713407 (2017) — Biorhizome: A Biosynthetic Platform for Colchicine Biomanufacturing. · Frontiers in plant science
5.PMID: 32699417 (2020) — Discovery and engineering of colchicine alkaloid biosynthesis. · Nature
Government sources
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
10.PMID: 36533687 (2023) — Isolation of a new cytotoxic colchinoid from Gloriosa superba roots. · Natural product research
11.PMID: 40642599 (2025) — Chitosan-encapsulated Gloriosa superba nanoparticles suppress cervical cancer by inhibiting SKA3-mediated PI3K/AKT/mTOR pathway. · Cytotechnology
12.PMID: 27324655 (2016) — Case report: a rare case of attempted homicide with Gloriosa superba seeds. · BMC pharmacology & toxicology
13.PMID: 36964265 (2023) — Docking experiments suggest that gloriosine has microtubule-targeting properties similar to colchicine. · Scientific reports
14.PMID: 26060369 (2015) — Gloriosa superba ingestion: Hair loss and acute renal failure. · Indian journal of nephrology
15.PMID: 36033689 (2022) — Antiproliferative Potential of Gloriosine: A Lead for Anticancer Drug Development. · ACS omega
16.PMID: 27765363 (2016) — Coadministration of a Gloriosa superba extract improves the in vivo antitumoural activity of gemcitabine in a murine pancreatic tumour model. · Phytomedicine : international journal of phytotherapy and phytopharmacology
17.PMID: 30888889 (2019) — Epidemiology, toxicokinetics and biomarkers after self-poisoning with Gloriosa superba. · Clinical toxicology (Philadelphia, Pa.)